Press Releases

Date	Title	PDF Version
Jun 29, 2020	ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS)
Jun 24, 2020	Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint
Jun 17, 2020	Alexion Charitable Foundation Announces First Rare Belonging® Grants
Jun 17, 2020	Alexion to Present at the 2020 Bank of America Virtual Napa Biotech Conference
Jun 04, 2020	Alexion to Present at the 41st Annual Global Goldman Sachs Healthcare Conference
May 14, 2020	Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association
May 06, 2020	Alexion Reports First Quarter 2020 Results
May 05, 2020	Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference
May 05, 2020	Alexion to Acquire Portola
May 01, 2020	Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)

Search